---
figid: PMC3921546__WJG-20-943-g001
figtitle: Representation of epidermal growth factor receptor pathway in response to
  therapy with anti-epidermal growth factor receptor inhibitors in wild-type and mutant
  patients
organisms:
- NA
pmcid: PMC3921546
filename: WJG-20-943-g001.jpg
figlink: /pmc/articles/PMC3921546/figure/F1/
number: F1
caption: 'Representation of epidermal growth factor receptor pathway in response to
  therapy with anti-epidermal growth factor receptor inhibitors in wild-type and mutant
  patients. A: The binding of monoclonal antibodies (mAb) to EGFR normally causes
  the blockage (indicated with a red cross) of downstream RAS/RAF/MAPK and PI3K/AKT/mTOR
  signalling pathways and so the blockage of gene expression and cell cycle progression;
  B: Mutations in any gene of this pathway (indicated with a red star) cause a constitutive
  activation of the pathway leading to gene expression, upregulated proliferation,
  impaired differentiation and no response to monoclonal inhibitors. EGFR: Epidermal
  growth factor receptor; KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
  gene; BRAF: V-raf murine sarcoma viral oncogenes homolog B1; MEK: MAPK/ERK kinase;
  ERK: Extracellular signal-regulated kinases; PTEN: Phosphatase and tensin homolog;
  PI3K: Phosphatidylinositide-3-kinases; AKT: Protein Kinase B (PKB); mTOR: Mammalian
  target of rapamycin.'
papertitle: Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment
  of colorectal cancer.
reftext: Fabio Copped√®, et al. World J Gastroenterol. 2014 Jan 28;20(4):943-956.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9468285
figid_alias: PMC3921546__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC3921546__F1
ndex: a0aa1c3f-def8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3921546__WJG-20-943-g001.html
  '@type': Dataset
  description: 'Representation of epidermal growth factor receptor pathway in response
    to therapy with anti-epidermal growth factor receptor inhibitors in wild-type
    and mutant patients. A: The binding of monoclonal antibodies (mAb) to EGFR normally
    causes the blockage (indicated with a red cross) of downstream RAS/RAF/MAPK and
    PI3K/AKT/mTOR signalling pathways and so the blockage of gene expression and cell
    cycle progression; B: Mutations in any gene of this pathway (indicated with a
    red star) cause a constitutive activation of the pathway leading to gene expression,
    upregulated proliferation, impaired differentiation and no response to monoclonal
    inhibitors. EGFR: Epidermal growth factor receptor; KRAS: v-Ki-ras2 Kirsten rat
    sarcoma viral oncogene homolog gene; BRAF: V-raf murine sarcoma viral oncogenes
    homolog B1; MEK: MAPK/ERK kinase; ERK: Extracellular signal-regulated kinases;
    PTEN: Phosphatase and tensin homolog; PI3K: Phosphatidylinositide-3-kinases; AKT:
    Protein Kinase B (PKB); mTOR: Mammalian target of rapamycin.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - KRAS
  - NRAS
  - PTEN
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - mab
  - Egfr
  - Pten
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Mtor
  - Tor
  - Cancer
  - Lung cancer
---
